- Home
- GNTX vs TERN Comparison
GNTX vs TERN Comparison
Compare GNTX & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTX | TERN |
|---|---|---|
| Founded | 1974 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.5B |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GNTX | TERN |
|---|---|---|
| Price | $23.26 | $41.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $28.33 | ★ $48.60 |
| AVG Volume (30 Days) | ★ 2.2M | 1.7M |
| Earning Date | 05-01-2026 | 04-17-2026 |
| Dividend Yield | ★ 2.03% | N/A |
| EPS Growth | N/A | ★ 11.81 |
| EPS | ★ 1.74 | N/A |
| Revenue | ★ $2,534,268,965.00 | N/A |
| Revenue This Year | $6.42 | N/A |
| Revenue Next Year | $4.56 | N/A |
| P/E Ratio | $13.61 | ★ N/A |
| Revenue Growth | ★ 9.55 | N/A |
| 52 Week Low | $20.28 | $1.87 |
| 52 Week High | $29.38 | $48.26 |
Technical Indicators
Market Signals| Indicator | GNTX | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 41.91 | 65.42 |
| Support Level | $22.70 | $39.15 |
| Resistance Level | $23.61 | $48.26 |
| Average True Range (ATR) | 0.53 | 2.09 |
| MACD | -0.12 | 0.33 |
| Stochastic Oscillator | 9.07 | 93.24 |
Price Performance
Historical ComparisonAbout GNTX Gentex Corporation
Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.